LH vs VRTX: fair value comparison
Labcorp Holdings Inc. and Vertex Pharmaceuticals Incorporated · Updated 2026-09-12
LH currently screens as fairly valued while VRTX screens as overvalued. Within Healthcare, LH currently sits closer to the top of our discount ranking. VRTX carries the stronger quality grade.
| LH | VRTX | |
|---|---|---|
| Verdict | Fairly valued | Overvalued |
| Last price | $311.54 | $515.44 |
| 12-month range | $251.66–$327.61 | $423.92–$547.65 |
| Sector rank | #88 of 113 Healthcare | #90 of 113 Healthcare |
| Quality grade | D | A |
| Leverage | Moderate | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: LH fair value analysis · VRTX fair value analysis